Walleye Capital’s Protalix BioTherapeutics PLX Stock Holding History

Walleye Capital’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-220,089	Closed	-$293	–	2264
2021 Q3	$293	Sell	220,089 -126,450	-36%	-$192K	0.01%	1024
2021 Q2	$662	Buy	+346,539	New	+$1.19M	0.02%	640
2020 Q3	–	Sell	-58,609	Closed	-$222K	–	940
2020 Q2	$222K	Buy	+58,609	New	+$200K	0.05%	404

Other funds holding PLX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Walleye Capital's PLX Position: Q4 2021 in Review

Walleye Capital sold out of Protalix BioTherapeutics (PLX) in Q4 2021, closing a stake of 220,089 shares — an estimated $293 sold.

Walleye Capital first reported a position in PLX in Q2 2020 and held it in 3 quarters. The position peaked at $222K in Q2 2020. 31 funds tracked by Wall St. Rank hold PLX as of Q4 2021.

Walleye Capital reported no remaining Protalix BioTherapeutics position as of Q4 2021 after selling out during the quarter.
Walleye Capital sold 220,089 Protalix BioTherapeutics shares in Q4 2021, an estimated $293.
Walleye Capital first reported a position in Protalix BioTherapeutics in Q2 2020 and held it in 3 quarters.
Walleye Capital's Protalix BioTherapeutics position peaked at $222K in Q2 2020.
31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.